ENDPAC新发糖尿病胰腺癌风险模型在英国初级保健中的外部验证
本研究基于英国ORCHID初级保健哨兵网络开展回顾性队列研究,在70050名≥50岁新发糖尿病成人中验证ENDPAC算法。185人(0.26%)发生胰腺癌,ENDPAC的AUC为0.733,最佳切点≥3时敏感性62.6%、特异性72.3%、PPV 0.6%、NPV 99.9%。ENDPAC在英国初级保健中具有中等区分度,可作为低成本的自动化风险分层工具。
要点
- ENDPAC在英国新发糖尿病人群中AUC为0.733,区分度中等。
- 切点≥3时27.6%被归为高风险,敏感性62.6%、特异性72.3%。
- PPV仅0.6%但NPV达99.9%,适合作为序贯诊断路径的初筛。
核心结论
- ENDPAC在英国初级保健新发糖尿病人群中表现出中等区分度,可低成本自动化识别胰腺癌高风险者。
研究设计与样本
- 基于英国ORCHID国家初级保健哨兵网络的回顾性队列研究,纳入≥50岁且有HbA1c和体重数据的新发糖尿病成人。
主要发现
- 70050名新发糖尿病个体中185人(0.26%)发生胰腺癌,病例组年龄更大、HbA1c更高且诊断时体重下降更多。
- ENDPAC的AUC为0.733;最佳切点≥3将27.6%个体归为高风险,敏感性62.6%、特异性72.3%、PPV 0.6%、NPV 99.9%。
- 敏感性分析显示在不同测量时间窗和多次值处理方式下性能相似。
关键数值与推荐
- ENDPAC最佳切点为≥3分,该切点下高风险比例为27.6%。
- 切点≥3时敏感性62.6%、特异性72.3%、PPV 0.6%、NPV 99.9%。
临床怎么用
- 可将ENDPAC整合入常规系统,对新发糖尿病患者自动计算风险评分以辅助分层。
- 鉴于PPV较低,ENDPAC宜作为序贯诊断路径的初筛环节而非独立确诊工具。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic cancer has very low survival due to late diagnosis. Symptoms are often non-specific, complicating early detection in primary care. The Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) algorithm uses weight change, glycaemic control, and age at diabetes onset to identify new-onset diabetes (NOD) patients at increased pancreatic cancer risk. It was developed in the USA and has not been validated in the UK. Aim To validate ENDPAC in a UK primary care population and assess its predictive utility. Design and setting Retrospective cohort study using ORCHID, a national primary care sentinel network. Method Adults aged ≥50 with NOD and requisite glycated haemoglobin (HbA1c) and weight data were included. ENDPAC scores were calculated. Model performance was evaluated via discrimination, calibration, sensitivity, specificity, PPV and NPV. The Youden index identified optimal cutoffs. Sensitivity analyses assessed measurement timing, repeat HbA1c testing and multiple values. Results Among 70,050 individuals, 185 (0.26%) developed pancreatic cancer. Cases were older with higher HbA1c and greater weight loss at diagnosis. ENDPAC achieved an area under the curve (AUC) of 0.733. An optimal cutoff of ≥3 classified 27.6% of individuals as high-risk, with 62.6% sensitivity, 72.3% specificity, 0.6% PPV and 99.9% NPV. Sensitivity analyses showed similar performance across measurement windows and handling of multiple values. ENDPAC shows moderate discrimination in UK primary care. Although it has a relatively low PPV (0.6%), integration into routine systems could provide scalable, low-cost automated risk stratification, identifying people with NOD at higher pancreatic cancer risk as part of a sequential diagnostic pathway.
引用
- Price CA, Claridge H, de Lusignan S, et al. Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC): External validation using English sentinel network. Br J Gen Pract. 2026. PMID: 42392832. doi:10.3399/BJGP.2024.0253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。